


Technical Report No. 57

Analytical Method Validation and Transfer for Biotechnology Products

2012



PDA Analytical Method Validation And Transfer For Biotechnology Products Task Force Members

Authors

Stephan O. Krause, Ph.D., Chair, MedImmune

Florence Baudoux, Ph.D., GlaxoSmithKline

Pierre Douette, Ph.D., Eurogentec S.A.

Nicole Gibelin, Ph.D., Sanofi Pasteur, France

Alice E. Grebanier, Ph.D., Centocor R&D

Rajesh Krishnamurthy, Ph.D., Zyngenia, Inc.

Carl-Gustav, Millinger, Ph.D., Swedish Orphan
Biovitrum

Frank Moffatt, Ph.D., Solvias AG

Dwayne Neal, SAIC-Frederick, Inc.

Phillip Ramsey, SAIC-Frederick, Inc.

Michael Rooney, Ph.D., BioTechLogic

Melissa J. Smith, MJ Quality Solutions

Michael Warncke, Ph.D., Bayer HealthCare

Earl K. Zablackis, Ph.D., Sanofi Pasteur, USA

Contributors

Patricia W. Cash, Ph.D., MedImmune

Larissa Chirkova, Novozymes

Marta Germano, Pharming Technologies

Siegfried Giess, Ph.D., Paul-Ehrlich Institute

Rashmi Rawat, Ph.D., U.S. FDA

The content and views expressed in this Technical Report are the result of a consensus achieved by the authorizing Task Force and are not necessarily views of the organizations they represent.

Analytical Method Validation and Transfer for Biotechnology Products

Technical Report No. 57

ISBN: 978-0-939459-41-4

© 2012 Parenteral Drug Association, Inc.

All rights reserved.



Table of Contents

1.0 Introduction.....	1	4.4.1 AMV Protocol	34
1.1 Scope and Purpose.....	1	4.4.2 AMV Report	35
2.0 Glossary of Terms	4	5.0 Analytical Method Transfer	36
2.1 List of Abbreviations	9	5.1 Prerequisites to AMT.....	36
3.0 General Assessment of Method Validation		5.2 General AMT Strategy.....	37
Readiness	10	5.3 Design of Comparative (AMT) Test Studies	38
3.1 General Risk Assessment Process	13	5.3.1 Selecting AMT Performance	
3.2 Setting AMV Protocol Acceptance Criteria	16	Characteristics	38
3.2.1 Rationale.....	16	5.3.2 Sample Selection and	
3.2.2 Consistent Risk Assessment to Set		AMT Study Design	38
Acceptance Criteria.....	17	5.3.2.1 Specific AMT Study Design for	
3.3 Example for AMV Protocol Acceptance Criteria.....	18	Highly Variable Methods.....	40
3.3.1 Setting and Justifying Acceptance		5.4 Acceptance Criteria and Statistical Evaluation	41
Criteria for the AMV Protocol	19	5.4.1 Acceptance Criteria for AMT Study	41
4.0 Analytical Method Validation.....	20	5.4.2 Statistical Tests for AMT Studies	42
4.1 AMV Characteristics	22	5.5 Sample Preparation	43
4.1.1 Accuracy	22	5.6 Deviations and Failures	43
4.1.2 Repeatability Precision	22	5.6.1 Invalid Assays	43
4.1.3 Intermediate Precision.....	23	5.6.2 Handling of Outlying Results	
4.1.4 Reproducibility (Precision)	24	and Retesting	43
4.1.5 Specificity.....	24	5.6.3 AMT Study Extension	44
4.1.6 Linearity.....	24	5.7 AMT Documentation	44
4.1.7 Range	25	5.8 AMT Example.....	44
4.1.8 Detection Limit (DL).....	25	5.9 AMT Continuum	48
4.1.9 Quantitation Limit (QL)	26	6.0 Analytical Method Comparability	49
4.1.10 Typical AMV Execution Matrix	26	6.1 Replacing Analytical Methods	49
4.2 Additional AMV Characteristics		6.2 Demonstrating AMC in	
to be Considered	27	Post-Validation Studies	50
4.2.1 Assay Bias and Analytical		6.2.1 Qualitative Tests	50
Response Factors.....	29	6.2.2 Quantitative Tests.....	51
4.2.2 Stability of Samples, Standards, Controls,		6.3 Design of AMC Study	51
Reagents, and Material	29	6.3.1 Application and Acceptance Criteria	52
4.2.3 System Suitability	30	6.3.2 AMC Examples	52
4.2.4 Sample Suitability	30	6.3.2.1 Demonstrating Noninferiority	52
4.2.5 Statistical Data Reduction	31	6.3.2.2 Demonstrating Superiority.....	53
4.2.6 Robustness	31	6.3.2.3 Demonstrating Equivalence	54
4.2.7 Degradation	31	7.0 Analytical Method Maintenance	57
4.2.8 Significant Digits in Reported Results.....	32	7.1 Monitoring Analytical Method Performance.....	57
4.2.9 Validating Other Analytical Technologies	33	7.2 Periodic Review.....	58
4.3 Analytical Method Verification	33	7.3 Replacing Analytical Method Components.....	61
4.3.1 Verification Process.....	33	8.0 AMV Discrepancies/Failures	62
4.3.2 Verification Requirements.....	34	8.1 Investigation and Decision Process	63
4.3.3 Retrospective Data.....	34	9.0 References.....	65
4.4 AMV Documentation	34		

FIGURES AND TABLES INDEX

Figure 1.1-1	Analytical Method Life Cycle Steps from Selection to Qualification or Validation ... 2	Table 5.3.1-1	Examples of Method Types and AMT Performance Characteristics..... 38
Figure 1.1-2	Example of a Method Lifecycle from the Identification of the Intended Use to Post-Validation Maintenance..... 3	Table 5.3.2-1	Examples of AMT Execution Matrices and Acceptance Criteria 39
Figure 3.0-1	Example of Assessment of Method Validation Readiness Flow Path 10	Table 5.3.2.1-1	Type I and Type II errors..... 40
Table 3.0-1	General Method Readiness Assessment Guide..... 11	Table 5.3.2.1-2	General AMT Design Parameters and Considerations..... 41
Table 3.1-1	The Five General AMV Classes and Prospective AMV Studies 14	Table 5.7-1	Typical AMT Protocol Sections 44
Table 3.1-2	Points to Consider in Overall Risk Assessment for Analytical Methods . 15	Table 5.8-1	AMT Study Design 45
Table 3.1-3	General Risks to Patient and/or Firm. 16	Table 5.8-2	AMT Transfer Results 46
Figure 3.2.2-1	Risk-Based AMV Protocol Acceptance Criteria 18	Figure 5.8-1	Graphical Representation of Potency Results Per Potency Level Between Laboratories..... 47
Table 3.3-1	Historical Data for Manufacturing Process, Assay Performance, and Suggested Limits for Accuracy and (Intermediate) Precision..... 19	Figure 5.8-2	Graphical Representation of the Combined Percent Recoveries Between Laboratories for All Three Concentration Levels 48
Table 4.0-1	Minimum AMV Characteristics Per ICH Q2(R1) 20	Table 6.1-1	Suggested Statistics to Assess AMC for Each Method Performance Characteristic 50
Table 4.0-2	ICH Q2(R1) Requirements and Suggested Reported Results and Acceptance Criteria 21	Table 6.3.2.1-1	Results for the Noninferiority Test: Candidate Method vs. EP/USP Sterility . 53
Table 4.1.3-1	Intermediate Precision Matrix..... 23	Figure 6.3.2.1-1	95% Confidence Interval for Noninferiority Test: Candidate Method vs. EP/USP Sterility..... 53
Table 4.1.3-2	Mixed Linear Model Results for Intermediate Precision Matrix..... 24	Table 6.3.2.2-1	Results for the Superiority Test: New Method (7x per week) vs. EP/USP Sterility (2x per week) 54
Table 4.1.10-1	Typical AMV Execution Matrix for a Quantitative Limit Test 27	Figure 6.3.2.2-1	95% Confidence Intervals for Superiority Test: Candidate Method vs. EP/USP Sterility 54
Table 4.2-1	ICH Q2(R1) Requirements and Suggested Reported Results and Acceptance Criteria.....28	Table 6.3.2.3-1	Equivalence Test Results Comparing SDS-PAGE (Reference) to CE 55
Table 4.2.2-1	Prospective Expiry Date Study Protocol for a Critical In-House Reagent 30	Figure 6.3.2.3-1	90% Confidence Intervals for Equivalence: Candidate Method vs. EP/USP Sterility 55
Table 4.2.8-1	Confirming Significant Digits in Reported Test Results 32	Figure 7.1-1	Combining Laboratory (Assay Control) and Manufacturing Control Charts ... 58
Table 4.3-1	Verification Characteristics for Typical Compendial Method Types and Resulting Specifications..... 34	Table 7.2-1	Suggested Checklist Items to Assess Validation Status..... 60
Table 4.4.1-1	Typical AMV Protocol Elements 35	Figure 8.0-1	Failing Acceptance Criteria – The “Recovery Mission” 62
Table 4.4.2-1	Typical AMV Report Elements 35	Table 8.1-1	Checklist of Most Common Questions and Possible Information Sources.... 64
Table 5.1-1	Suggested AMT Responsibility Matrix.. 37		

1.0 Introduction

This Technical Report (TR) provides risk-based guidance for Analytical Method Validation (AMV), which follows Analytical Method Development (AMD) or Analytical Method Qualification (AMQ), and contains risk-based guidance for other, related method lifecycle steps, such as Analytical Method Transfer (AMT).

The guidance provided here builds upon the International Conference on Harmonization (ICH) Q2 (R1) guidelines and includes additional considerations for analytical platform technology (APT) methods as well as the impact of stakeholder considerations, and essentially all modern quality expectations as recommended in the ICH Q8 (R2), Q9, and Q10 guidelines (1–4).

Similar to the manufacturing process, an analytical method can also be considered to be a process. The validation strategy for analytical methods could therefore conceptually follow those of Process Validation (5). AMV can then be defined as the collection and evaluation of data, from the analytical method development stage throughout routine QC testing, which establishes scientific evidence that an analytical method is capable of consistently delivering accurate and reliable results.

1.1 Scope and Purpose

This TR is to provide practical and strategic guidance to efficiently use historical data and knowledge to design suitable risk-based AMV studies, and set appropriate protocol acceptance criteria. The typical method lifecycle steps prior, during, and beyond the AMV studies are illustrated in **Figure 1.1-1**. The typical steps prior to validation, usually performed at early pharmaceutical development stages, are included in this figure to show the dependency among early- and late-stage lifecycle steps. The AMV process begins with the validation readiness assessment and continues with the post-validation steps, maintenance (validation continuum), transfer(s), comparability, as they may apply to the continuous demonstration of analytical method suitability. The typical sequence of all prevalidation, validation and post-validation steps, as illustrated in the bottom half of **Figure 1.1-1**, is reflected in the sequence of sections in this TR. Instead of dealing in great detail with many possible exceptions and special considerations, this TR is intended to provide practical guidance to typical development processes and AMV studies.

The guidance presented in this TR applies to all biotechnological manufacturers and all contract development and manufacturing organizations. This TR does not provide specific guidance for the timing of AMV study execution with respect to the parallel product development lifecycle stages or guidance for analytical instrument qualification.

It should be considered that various new analytical technologies and/or the use of Process Analytical Technology (PAT) methods may suggest some modification to the validation strategies presented here. Specific aspects for the validation of bioassays such as curve fitting models and statistical reference-to-sample parallelism requirements are not covered in this TR. Case-specific considerations for microbiological method validation such as statistical sampling and testing environment conditions are also not covered as they depend on the analytical methodology and the intended use.

AMV studies are typically executed for future routine-use methods but may not be required for analytical methods used in support of pharmaceutical development (5). **Figure 1.1-2** illustrates the two different analytical method lifecycle paths separated according to the intended use of a particular method. The intended use of a particular method can be assessed early as part of the overall quality target product profile (QTPP) and a method should be selected accordingly. The intended use should be further considered when developing, qualifying and validating analytical methods. For example, measuring a critical quality attribute (CQA) or a critical process parameter (CPP) may require a more rigorous approach to the overall validation process. The intended use of a method can change during the method and/or product lifecycle(s) due to a specification change or other reasons.